Related Experiment Video
Updated: May 9, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Long-term comparison of apical versus asymmetric hypertrophic cardiomyopathy
Sung-Hwan Kim1, Seon-Ok Kim, Seungbong Han
1Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea.
Insights
Apical hypertrophic cardiomyopathy (HCM) has similar survival to asymmetric HCM, but asymmetric HCM carries a higher risk of cardiac death. Beta-blocker use improved long-term outcomes for both hypertrophic cardiomyopathy types.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Apical hypertrophic cardiomyopathy (HCM) is often considered less severe than asymmetric HCM.
- Direct comparisons of clinical features and long-term outcomes between apical and asymmetric HCM are limited.
Purpose of the Study:
- To compare electrocardiographic findings and long-term mortality between patients with apical HCM and asymmetric HCM.
- To identify predictors of long-term outcomes in HCM patients.
Main Methods:
- Retrospective study of 796 patients (243 apical HCM, 553 asymmetric HCM).
- Long-term all-cause and cardiac mortality assessed using inverse probability of treatment weighting (IPTW) and propensity score matching (PSM).
Main Results:
- Asymmetric HCM showed significantly more QT prolongation, QRS widening, PR prolongation, and pathologic Q waves.
- Overall survival rates were similar (borderline significant difference: IPTW/PSM P=0.05).
- Asymmetric HCM was associated with significantly higher cardiac mortality (IPTW/PSM P=0.03). Beta-blocker use correlated with lower overall death.
Conclusions:
- While overall survival is comparable, asymmetric HCM presents a higher risk for cardiac death than apical HCM.
- No specific electrocardiographic predictor for long-term outcomes was identified.
- Beta-blocker therapy is associated with improved long-term survival in HCM patients.
Abstract:
Although apical hypertrophic cardiomyopathy (HCM) has been considered to be more benign than asymmetric HCM, few studies have directly compared their clinical features. We compared the electrocardiographic data and longterm outcomes between patients with apical HCM versus asymmetric HCM. This retrospective study enrolled 796 patients (243 apical HCM and 553 asymmetric HCM). We assessed long-term all-cause and cardiac mortalities using an inverse probability of treatment weighted (IPTW) method and propensity score matched (PSM) analysis. In patients with asymmetric HCM, QT prolongation, QRS widening, PR prolongation, and pathologic Q wave were significantly more frequent. The incidences of early repolarization were similar (11% in apical and 12% in asymmetric HCM, P = 0.19). The median follow-up duration was 6.5 years. There was a borderline significant difference in overall survival rates between the apical and asymmetric HCM groups (73% versus 69%, log rank P = 0.38, IPTW: P = 0.05, PSM: P = 0.05). Regarding cardiac death, asymmetric HCM was more hazardous than apical HCM (89% versus 77%, log rank P = 0.04, IPTW: P = 0.03, PSM: P = 0.03). There was no electrocardiographic predictor for the long-term outcomes, although beta-blocker use was significantly associated with lower overall death (HR = 0.58, 95% CI = 0.41-0.81) and slightly lower cardiac death (HR = 0.86, 95% CI = 0.55-1.33). The overall survival rate of apical HCM was as high as that of asymmetric HCM, but the cardiac survival rate was significantly lower in patients with asymmetric HCM. Beta-blocker use was associated with better long-term outcomes.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
